Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

27
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
27
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

358
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
358
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

871
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
871
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

317
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
317
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of 8 weeks Federation of International Football Association 11+ S Program on Upper Limb Strength, Power, Co-ordination and Reaction Time in Amateur Level Badminton Players - A Pilot Study.

Journal of orthopaedic case reports·2026
Same author

Identification of novel signal of DRESS associated with antibiotics: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database.

European journal of clinical pharmacology·2026
Same author

The predictive value of 24-hour urinary calcium for kidney stone risk in primary hyperparathyroidism: insight from a retrospective study of parathyroid adenoma cases.

Frontiers in endocrinology·2025
Same author

Challenges and advances in the development of antidotes against A-series nerve agents.

Archives of toxicology·2025
Same author

Effects of individual, health system and neighborhood risks on diabetes health outcomes among emerging adults with type 1 diabetes.

Diabetes research and clinical practice·2025
Same author

Human Paraoxonase 1: From Bloodstream Enzyme to Disease Fighter & Therapeutic Intervention.

Current protein & peptide science·2024

Related Experiment Video

Updated: Sep 11, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.5K

Transient Proteinuria Induced by High-Dose Rosuvastatin.

Khushi Goyal1, Sandeep S Soman2, Arti Bhan3

  • 1Dayanand Medical College & Hospital, Ludhiana, Punjab, India.

AACE Endocrinology and Diabetes
|August 11, 2025
PubMed
Summary

High-dose rosuvastatin can cause transient proteinuria, a reversible side effect. Switching to atorvastatin resolved the proteinuria, highlighting the need for individualized statin therapy and monitoring.

Keywords:
atorvastatinprotein excretionproteinuriarosuvastatinstatin-induced side effects

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.2K

Related Experiment Videos

Last Updated: Sep 11, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.2K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • A 70-year-old woman with multiple comorbidities including diabetes, hypertension, and hyperlipidemia presented with non-ST elevation myocardial infarction.
  • She was initiated on high-dose rosuvastatin therapy for hyperlipidemia management.

Observation:

  • Following three months of high-dose rosuvastatin, the patient developed significant proteinuria (albumin-to-creatinine ratio of 344.1) and muscle cramps.
  • Renal function remained stable, with a glomerular filtration rate above 70 mL/min/1.73 m².
  • Pre-treatment urine albumin-to-creatinine ratios were within normal limits (<30 mg/g).

Findings:

  • High-dose rosuvastatin therapy was associated with the development of transient, dose-dependent proteinuria.
  • Proteinuria resolved after discontinuing rosuvastatin and switching to a combination of atorvastatin and ezetimibe.
  • Lipid levels were effectively managed with the alternative medication regimen.

Implications:

  • This case underscores the importance of monitoring for proteinuria as a potential side effect of high-dose statin therapy, particularly rosuvastatin.
  • Individualized treatment approaches and careful dose titration are crucial for optimizing statin efficacy and patient safety.
  • Prompt recognition and management of statin-induced proteinuria can prevent potential renal complications and improve patient adherence to lipid-lowering therapy.